Caisson’s HEPtune® technology was invented by Chief Scientist and University of Oklahoma Professor Dr. Paul DeAngelis, a world renowned glycobiology and enzyme specialist.
Caisson utilizes a partnership driven business model works closely with its partners to advance its HEPtune technology platform.
2017 – Caisson introduces HEPtune® linker technology for enhanced antibody drug conjugates (ADC).
2016 – Caisson announces global manufacturing partnership with Corden Pharma to enable cGMP manufacturing of heparosan polymers.
2015 – Caisson completes internal research of HEPtune® production process and initiates preparations to transfer and scale up with commercial manufacturer.
2014 – Caisson expands partnership with Novo Nordisk for the commercial rights to HEPtune® technology for additional exclusive and non-exclusive tracks.
2012 – Caisson enters Development and License Agreement with Novo Nordisk after successfully completing feasibility studies.
2011 – Caisson leverages $1.6 million EDGE Award to enable chemistry, manufacturing, and controls for its proprietary heparosan products.
2009 – Heparinex licenses rights to drug delivery applications to newly formed subsidiary Caisson Biotech, LLC.